Desjardins Has Pessimistic View of TSE:INO Q4 Earnings

Inovalis Real Estate Investment Trust (TSE:INO) – Analysts at Desjardins dropped their Q4 2024 earnings per share (EPS) estimates for Inovalis Real Estate Investment Trust in a report issued on Monday, November 11th. Desjardins analyst A. Leon now anticipates that the company will post earnings of ($0.01) per share for the quarter, down from their previous forecast of $0.01. Desjardins also issued estimates for Inovalis Real Estate Investment Trust’s FY2025 earnings at ($0.06) EPS and FY2026 earnings at ($0.14) EPS.

Inovalis Real Estate Investment Trust (TSE:INO) last issued its earnings results on Thursday, November 7th. The company reported C($0.29) EPS for the quarter. The firm had revenue of C$3.52 million during the quarter.

Inovalis Real Estate Investment Trust Stock Performance

Inovalis Real Estate Investment Trust Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.